大巴黎地区COVID-19疫情期间ECMO网络组织与临床结局:多中心队列研究
该多中心队列研究分析了2020年3月8日至6月3日大巴黎地区17个ICU中302例接受ECMO的COVID-19相关重度ARDS成人患者,90天生存率为46%,死亡主要原因为多器官衰竭和感染性休克;中心年静脉-静脉ECMO例数≥30例与90天生存改善独立相关。
要点
- COVID-19相关重度ARDS接受ECMO者90天生存率为46%。
- 年静脉-静脉ECMO≥30例的中心与90天生存改善独立相关。
- 气管插管至ECMO时间缩短与90天生存改善独立相关。
核心结论
- COVID-19相关重度ARDS接受ECMO者90天生存率为46%,中心年静脉-静脉ECMO例数≥30例与生存改善独立相关。
研究设计与样本
- 多中心队列研究纳入2020年3月8日至6月3日大巴黎地区17个ICU中302例实验室确诊SARS-CoV-2感染并接受ECMO的重度ARDS成人患者。
主要发现
- 302例患者中位年龄52岁(IQR 45-58),男性235例(78%),165例(55%)由移动ECMO团队置管后转运。
- ECMO期间270例中115例(43%)发生大出血事件(其中27例颅内出血),301例中130例(43%)接受肾脏替代治疗,294例中53例(18%)发生肺栓塞。
- 138例(46%)在ECMO启动后90天存活,最常见死亡原因为多器官衰竭(53例,18%)和感染性休克(47例,16%)。
- 移动ECMO置管与现场置管患者生存无显著差异。
临床怎么用
- 应倡导在年静脉-静脉ECMO例数较多的中心早期实施ECMO管理,并通过集中化和指征调控避免资源短缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Île-de-France region (henceforth termed Greater Paris), extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) was considered early in the COVID-19 pandemic. We report ECMO network organisation and outcomes during the first wave of the pandemic. METHODS: In this multicentre cohort study, we present an analysis of all adult patients with laboratory-confirmed SARS-CoV-2 infection and severe ARDS requiring ECMO who were admitted to 17 Greater Paris intensive care units between March 8 and June 3, 2020. Central regulation for ECMO indications and pooling of resources were organised for the Greater Paris intensive care units, with six mobile ECMO teams available for the region. Details of complications (including ECMO-related complications, renal replacement therapy, and pulmonary embolism), clinical outcomes, survival status at 90 days after ECMO initiation, and causes of death are reported. Multivariable analysis was used to identify pre-ECMO variables independently associated with 90-day survival after ECMO. FINDINGS: The 302 patients included who underwent ECMO had a median age of 52 years (IQR 45-58) and Simplified Acute Physiology Score-II of 40 (31-56), and 235 (78%) of whom were men. 165 (55%) were transferred after cannulation by a mobile ECMO team. Before ECMO, 285 (94%) patients were prone positioned, median driving pressure was 18 cm H2O (14-21), and median ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen was 61 mm Hg (IQR 54-70). During ECMO, 115 (43%) of 270 patients had a major bleeding event, 27 of whom had intracranial haemorrhage; 130 (43%) of 301 patients received renal replacement therapy; and 53 (18%) of 294 had a pulmonary embolism. 138 (46%) patients were alive 90 days after ECMO. The most common causes of death were multiorgan failure (53 [18%] patients) and septic shock (47 [16%] patients). Shorter time between intubation and ECMO (odds ratio 0·91 [95% CI 0·84-0·99] per day decrease), younger age (2·89 [1·41-5·93] for ≤48 years and 2·01 [1·01-3·99] for 49-56 years vs ≥57 years), lower pre-ECMO renal component of the Sequential Organ Failure Assessment score (0·67, 0·55-0·83 per point increase), and treatment in centres managing at least 30 venovenous ECMO cases annually (2·98 [1·46-6·04]) were independently associated with improved 90-day survival. There was no significant difference in survival between patients who had mobile and on-site ECMO initiation. INTERPRETATION: Beyond associations with similar factors to those reported on ECMO for non-COVID-19 ARDS, 90-day survival among ECMO-assisted patients with COVID-19 was strongly associated with a centre's experience in venovenous ECMO during the previous year. Early ECMO management in centres with a high venovenous ECMO case volume should be advocated, by applying centralisation and regulation of ECMO indications, which should also help to prevent a shortage of resources. FUNDING: None.
引用
- Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med. 2021. PMID: 33887246. doi:10.1016/S2213-2600(21)00096-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。